Transinsight's GoPubMed with Social Networking Features for Biomedical Experts

Biomedical research happens in networks of researchers. Social networking web sites like FaceBook, LinkedIn and Xing use personal networks to establish contacts. On these sites, however, connections must be defined by the users themselves. For the first time, GoPubMed now completely and automatically extracts collaboration networks from millions of biomedical science publications. For each concept in the selected semantic background knowledge, GoPubMed's "Hot-Topic-View" shows the collaboration network between top authors in this field of research. Collaboration networks can now be experienced and visualized. GoPubMed also now allows these networks to be searched for possible experts and collaboration partners, a feature which leads to tremendous time saving when searching for appropriate experts. This feature is especially important in a specialized scientific world where it is becoming more and more vital to set up temporary teams of highly specialized experts.

"Some author names like Lee S., Smith J. and Müller C. appear over 20,000 times! We have solved the technical challenge of disambiguating the authors into single individuals with our semantic search technology, which in a way functions like the network of the brain", says Prof. Dr. Michael Schroeder, CSO and co-founder of Transinsight. If two articles share the same author, GoPubMed evaluates their similar properties. The system hereby takes into account that the author of each paper often publishes about similar research topics, with the same co-authors and in the same journals. The research topics are thereby connected to the concepts of the semantic network in the background. The more concepts two articles have in common and the shorter the semantic distance in the network is, the more likely it is that the articles were written by the same person. This approach leads to impressive accuracy. If at any point the system is not correct, it can be corrected by the users.

"GoPubMed is an essential step in significantly easing the finding of complexly networked information", according to Prof. Dr. Michael Brand, Director of the BioInnovation Center in Dresden. "The semantic approach is unparalleled worldwide, and I'm excited that such a development, which would be expected to come from Palo Alto's Stanford University in the Silicon Valley in California, today comes instead from Dresden," says Brand.

For further information, please visit:
www.GoPubMed.com

Related news articles:

About Transinsight
Founded in 2005, Transinsight is focused on software solutions for the life sciences providing products for knowledge-based technologies. The flagship product, www.gopubmed.com, a well established biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof. Transinsight works in close collaboration with the Technical University Dresden. For further information, visit www.transinsight.com.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...